WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 406591
Description: YL-109 has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. YL-109 repressed the sphere-forming ability and the expression of stem cell markers in MDA-MB-231 mammosphere cultures. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells by inhibiting the oncogenic pathway. YL-109 induced CHIP transcription because of the recruitment of the aryl hydrocarbon receptor (AhR) to upstream of CHIP gene in MDA-MB-231 cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhR knockdown in MDA-MB-231 cells. YL-109 inhibits cell growth and metastatic potential by inducing CHIP expression through AhR signaling and reduces cancer stem cell properties in MDA-MB-231 cells.
MedKoo Cat#: 406591
Chemical Formula: C14H11NO2S
Exact Mass: 257.05105
Molecular Weight: 257.31
Elemental Analysis: C, 65.35; H, 4.31; N, 5.44; O, 12.44; S, 12.46
Synonym: YL109; YP-109; YP 109.
IUPAC/Chemical Name: 4-(benzo[d]thiazol-2-yl)-2-methoxyphenol
SMILES Code: COC1=CC(C2=NC3=CC=CC=C3S2)=CC=C1O
1: Hiyoshi H, Goto N, Tsuchiya M, Iida K, Nakajima Y, Hirata N, Kanda Y, Nagasawa K, Yanagisawa J. 2-(4-Hydroxy-3-methoxyphenyl)-benzothiazole suppresses tumor progression and metastatic potential of breast cancer cells by inducing ubiquitin ligase CHIP. Sci Rep. 2014 Nov 18;4:7095. doi: 10.1038/srep07095. PubMed PMID: 25403352; PubMed Central PMCID: PMC4235287.